Pfizer stock gains after Q3 beat and higher 2026 outlook

Published on 11/05/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock traded at 27.63 euros on Thursday afternoon after the company raised its 2026 outlook. Newer products powered growth.

Pfizer raises outlook after strong quarter

Third-quarter revenue exceeded expectations as newer and acquired products offset weaker COVID-19 sales.
Pfizer lifted its 2026 revenue range and raised adjusted diluted earnings guidance.
Management highlighted pipeline progress, productivity gains and a planned return to growth toward the end of the decade.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer raised its full-year 2026 revenue and adjusted earnings outlook on November 3 after third-quarter sales exceeded expectations. The pharmaceutical company said commercial execution, cost discipline and demand for recently launched and acquired products supported the higher forecast. The details were published in Pfizer's third-quarter results update.

Pfizer generated USD 16.583 billion in third-quarter revenue, compared with USD 16.654 billion a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. Revenue from launched and acquired products increased 32% operationally to USD 3.8 billion, helping offset lower sales of COVID-19 products and pressure in parts of the Prevnar portfolio.

New products offset COVID pressure

Blood thinner Eliquis remained a key contributor, with quarterly sales of USD 2.52 billion, up 25% year over year. Cancer treatment Padcev also helped drive the quarter, while Pfizer identified Vyndaqel, Nurtec and Lorbrena among the products supporting growth. The company said the commercial performance reflected contributions from newer medicines as it works to reduce its dependence on pandemic-related products.

Adjusted diluted earnings per share reached USD 0.87, ahead of the USD 0.73 analyst consensus cited by CNBC. Reported diluted earnings per share were USD 0.56. Pfizer said the adjusted figure included a USD 0.10-per-share charge related to its Innovent transaction.

The company now expects 2026 revenue of USD 62.0 billion to USD 64.0 billion, up from its previous range of USD 60.5 billion to USD 62.5 billion. The midpoint increased by USD 1.5 billion. Adjusted diluted earnings guidance rose to USD 2.95 to USD 3.05 per share from USD 2.80 to USD 3.00. Pfizer maintained its expectation for approximately USD 4 billion in full-year COVID product revenue, with most Comirnaty sales expected during the fourth quarter vaccination season.

Pipeline remains central to valuation

Pfizer said it invested USD 8.3 billion in research and development during the first nine months of 2026 across oncology, vaccines, inflammation and immunology, and internal medicine. Chief Executive Albert Bourla said the company sees a path toward meaningful growth, supported by commercial execution, productivity improvements and progress in late-stage research.

Pfizer stock traded at 27.63 euros on Lang & Schwarz at 14:01 CET on Thursday, November 5, 1.66% above the Xetra close of Wednesday, November 4, at 27.18 euros. Investors will now focus on the durability of growth from newer products, the timing of pipeline milestones and Pfizer's 2027 guidance, which management plans to provide around mid-December. The real-time quote of Pfizer stock remains a key reference for daily trading.